Angelo Dipasquale

Just out in @ESMO_Open our large experience exploring prognostic signature of patients with astrocytoma IDHm G4‼️🤩 Shedding some light on this “grey-zone” entity between IDHm and IDHwt gliomas! 🔦🧠 @EANOassociation sciencedirect.com/science/articl…

New online! Time as an unmeasured ‘dose’ in oncology: introducing time budgeting as a design principle for cancer care dlvr.it/TS8L67

Review @NatureCancer @BizarMd @elhamazizi @Columbia Single-cell and spatial profiling in cancer biology and clinical oncology nature.com/articles/s4301…

Evolution of bispecific and multispecific antibodies in cancer therapy - The Lancet Regional Health – Europe thelancet.com/journals/lanep…

KRAS inhibitors have been used to treat pancreatic cancer, but can they PREVENT cancer from occurring altogether? In @ScienceMagazine from @PennCancer Cancer interception with KRAS inhibitors in preclinical models of #PancreaticCancer science.org/doi/10.1126/sc…

Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics Great review👇 nature.com/articles/s4157…

Out on @JNeurooncol our proof-of-concept experience exploring IDH mutation blockade after surgery in patients with WHO Grade 3 IDH+ gliomas! link.springer.com/article/10.100…

TIGIT as example of the Network Effect we are living in drug discovery nature.com/articles/d4157…

Check out this real world (England) data series of the impact of maintenance pemetrexed in 1st line NSCLC Median OS of 18.6 mo vs 19.5 Mo (not significant) with or without maintenance pemetrexed in 1000 pt case series: sciencedirect.com/science/articl…

A letter to editor we received and our response to it, both published in the February edition of @TheLancetOncol. Please read both and decide for yourself.

What if we’ve been overdosing immunotherapy all along? In our Ph III DELII study, 20 mg nivolumab q2w beat chemo in OS, with less toxicity, better QoL. It's time to rethink ICI dosing-for science and equity! ascopubs.org/doi/10.1200/JC… @JCO_ASCO @OncoAlert @TataMemorial @SuyogCancer

Artificial intelligence agents in cancer research and oncology - Truhn 2026, Nature Reviews Cancer

Interpreting the results of noninferiority trials: a review nature.com/articles/s4141… via @petersasieni et al

Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer cancertreatmentreviews.com/article/S0305-…

Preliminary phase 1 results of INCB161734, a novel KRAS G12D inhibitor, alone or with CTx for advanced/metastatic PDAC #ASCOGI26 👉ORR 37%, DCR: 78% 👉No safety signal in combination with CTx 🧐RAS💊 is rapidly expanding & moving to 1st line @myesmo @ASCO

A fascinating new analysis in @JAMANetworkOpen (Nov 2025) highlights a paradox many clinicians recognize but rarely discuss openly: PARP inhibitors dramatically improve PFS… yet OS differences remain blurred. Why? Because in nearly all major trials, crossover allows placebo patients to receive PARP at progression — narrowing survival curves and diluting OS signals. Is this PFS gain meaningful? For many patients: absolutely. It means longer chemo-free intervals, fewer complications, and the psychological relief of delaying relapse. The real question becomes: How much is that extra “quality time” worth — especially given the 2.4× higher risk of Grade 3–4 toxicity? #OvarianCancer #PARPInhibitors #Oncology #JAMA #GynecologicOncology #BRCA #CancerResearch #PrecisionMedicine

🚀 KRAS: From “Undruggable” to the Hottest Target in Oncology 🔥🧬 KRAS is the most mutated oncogene in cancer - yet for decades it was “undruggable.” 2025 marks a turning point. A brand-new Signal Transduction & Targeted Therapy review lays out the ENTIRE evolution: • Why KRAS drives PDAC, CRC, NSCLC • Why G12C inhibitors work but only partly • Why resistance is inevitable • What the next wave of KRAS therapies looks like 🔑 Key takeaways: 🧩 KRAS mutations = ~30% of all cancers – PDAC: 80–90% – CRC: ~40% – NSCLC: ~20% (G12C dominant) 🧬 Approved “OFF-state” inhibitors: •Sotorasib •Adagrasib ➡️ ORR ~30–40%, PFS ~6 months. ➡️ Resistance? Guaranteed. 🔥 Major resistance mechanisms: – Secondary KRAS mutations (Y96D/S, G13D, A59…) – RTK pathway upregulation – EMT & squamous transformation – KRAS amplification – KEAP1/STK11/TP53 co-mutation biology 💡 The future = multi-modal KRAS targeting: – Pan-RAS inhibitors – G12D inhibitors (MRTX1133-like) – SOS1/SHP2 inhibitors combos – KRAS degraders (PROTACs) – KRAS vaccines & cell therapies – RNA & antisense therapeutics 🧠 The review beautifully shows KRAS as a signaling “master switch” with MAPK, PI3K, Ral, RAC1, Hippo/YAP-TAZ crosstalk explaining why single-agent inhibition fails. 🎯 Bottom line: KRAS is no longer undruggable - it’s just very hard to drug. The next breakthroughs will come from combos + pan-KRAS + epigenetic modulation + TME targeting. 🔖 Save this - it’s THE 2025 roadmap for KRAS-targeted therapy. 📖 Full paper cited below. #OncoTwitter #MedTwitter #LCSM #GIOnc #TargetedTherapy @myESMO @OncoAlert @ESMO_Open

Do we really know how many patients derive long-term benefits from immunotherapy? Nice coverage of our new work by @AlysonHaslam, with @VPrasadMDMPH @vkprasadlab Check it out and subscribe for free at "The Oncology Shot" 👉 theoncologyshot.com/p/when-the-fol…

Phenomenal (and sobering) review on treatment options in NSCLC post PD1. Crazy how nothing , even combos cannot beat docetaxel in 2nd line in large randomized P3s! PFS stuck on 4-5 months, OS HR ~0.85 at best. TROP2 ADCs were the latest casualties (both dato and Trodelvy) but it remains to be seen whether other topo1-ADCs can perform better or maybe topo1 is just the wrong payload in NSCLC (as opposed to breast cancer where both ADCs are highly effective). Data from other topo1-based ADCs (cMET, TA-MUC1, Nectin4) suggest there is still room for optimism imo nature.com/articles/s4157…

Will A.I. lead to de-skilling of physicians? And if so what can be done to preempt it? @tberzin and I address this in a new @TheLancet piece thelancet.com/journals/lance…

Unresectable stage III non-small-cell lung cancer: state of the art and challenges Great review👇 nature.com/articles/s4157…